Indiana Biosciences Research Institute Welcomes Dr. Ari Landon as Chief Scientific Business Development Officer

Indianapolis, IN — October 14, 2025 — The Indiana Biosciences Research Institute (IBRI) is pleased to announce the appointment of Ari Landon, PhD, MBA, as Chief Scientific Business Development Officer.

Dr. Landon joins the IBRI with a distinguished background spanning biomedical research, biotechnology investment, and pharmaceutical leadership. He earned his PhD in Biochemistry from the University of Maryland School of Medicine, completed a fellowship in Pharmacology at Yale University, and holds an MBA in Strategy and Leadership from the NYU Stern School of Business.

Dr. Landon began his career as a scientist studying the mechanistic drivers of oncology, where he discovered a novel mechanism of mRNA translation and identified therapeutic strategies for malignant B-cells. His career has since bridged science and business, leading investments in early-stage therapeutics, directing research and development at Rafael Holdings, and overseeing diligence and licensing for oncology assets.

He later founded Fargo Biotechnologies with collaborators from Princeton University and Massachusetts Institute of Technology and most recently served at Elevate Ventures, managing one of the nation’s largest early-stage life science portfolios.

At the IBRI, Dr. Landon will lead efforts to create a sustainable research enterprise, overseeing scientific partnerships, revenue generation, and business development strategies that strengthen the Institute’s global impact.

“We are pleased to welcome Dr. Landon to the IBRI,” said Alan Palkowitz, PhD, President and CEO. “His unique combination of scientific insight and business acumen will be instrumental in expanding our translational research and innovation ecosystem.”